- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.11.25 | Vaximm and BCME link on oral cancer immunotherapy platform | ||
| 21.11.25 | "Reckless and harmful": experts weigh in on CDC's autism-vaccine link stance | ||
| 21.11.25 | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| 21.11.25 | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| 21.11.25 | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | ||
| 20.11.25 | CPHI 2025: linker innovation paves the way for a wave of new ADCs | ||
| 20.11.25 | Merck KGaA eyes new Parkinson's disease assets with $3bn Valo partnership | ||
| 20.11.25 | Moderna to onshore drug product manufacturing to Massachusetts | ||
| 20.11.25 | Regeneron's Eylea franchise boosted by pair of FDA approvals | ||
| 20.11.25 | Novartis taps North Carolina as new manufacturing hub location | ||
| 20.11.25 | Pfizer and Tris agree with Texas over ADHD drug allegations | ||
| 20.11.25 | EC authorises Roche's Lunsumio SC for follicular lymphoma | ||
| 19.11.25 | Alkermes prevails over Lundbeck in Avadel bidding war | ||
| 19.11.25 | Arrowhead nets first commercial win as siRNA drug garners FDA approval | ||
| 19.11.25 | FDA approves AbbVie's Epkinly to treat follicular lymphoma | ||
| 19.11.25 | CSL to pump $1.5bn into US plasma supply chain | ||
| 19.11.25 | USPTO grants patent to Genprex's Reqorsa gene therapy | ||
| 19.11.25 | Insmed receives EC approval for Brinsupri to treat NCFB | ||
| 18.11.25 | Redefining clinical trials in oncology and rare diseases across the Europe | ||
| 18.11.25 | Solve Therapeutics raises $120m as MSD joins list of backers | ||
| 18.11.25 | Merus and Halozyme link on subcutaneous petosemtamab | ||
| 18.11.25 | Johnson & Johnson to acquire Halda Therapeutics for $3.05bn | ||
| 17.11.25 | Henlius and Organon score first US Perjeta biosimilar approval | ||
| 17.11.25 | High-dose Spinraza inches closer to EU approval despite FDA setback | ||
| 17.11.25 | Medicxi unveils €500m fund for asset-centric biotechs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .